Home' Australian Pharmacist : Australian Pharmacist September 2015 Contents Australian Pharmacist September 2015 I © Pharmaceutical Society of Australia Ltd.
items in the product news section are prepared from information provided by the companies named in each
item. they are included for the information of psa members. it is up to the individual member to use their
professional judgment to decide on the merit or otherwise of each product mentioned. PSA neither endorses
nor confirms claims made in the items. ( where provided by the company references citing evidence are
included with the items.)
Australian Pharmacist is a professional journal. it will carry only advertising which is likely to be of interest to all
pharmacists and which does not reflect unfavourably directly or by implication on the pharmacy profession or
the professional practice of pharmacy. advertising which does not comply with this policy will be refused. it is
the responsibility of the advertisers to comply with the relevant Commonwealth and state law. advertising does
not constitute an endorsement by psa of the claims, products or services.
Read in greater detail more regularly than any other pharmacy title –
such constant behaviour means you can count on our readers to open
any issue and be seen!
» Greatest number of recipients opening and reading (82%)
» Greatest number of readers reading every issue (48%)
Engage with almost 18,800 PSA members every month
(15,500 pharmacists in print and 16,000 in digital form).
» Australian Pharmacist is read by 65% of community pharmacists
It has an extremely strong CPD program followed by more than
10,000 pharmacists – a typical monthly article receives 3000 plus
assessments, with highs over 4000!
» Greatest average proportion read (73%)
» Circulation 14,872 cab March 2013
TO ADVERTISE in the best-read pages in pharmacy media and give your campaign real
impact, and greater recognition, contact Tremain Media.
Ph: 02 9988 4689
Ph: 02 9871 5520
*Competitive Advantage Research August 2012 – 632 practicing community pharmacists
Answers for crossword on page 71.
Across: 1. Visual, 5. Design, 6. Space,
8. Options, 11. Pharmacy, 14. Dementia,
Down: 2. Safety, 3. Auditory, 4.
Information, 7. Alzheimers, 9. Size,
10. Friendly, 12. Attitude, 13. Familiar.
Tiger Balm Neck & Shoulder
For the first time in Australia, Tiger Balm
Neck & Shoulder Rub will feature in a TV
campaign on the brand news format.
The advertising began on Sunday 26 July.
A busy lifestyle can cause neck and
shoulder tension. Long hours sitting
at a desk, stress and constantly being
connected can be a real pain in the neck.
Neck pain is a significant issue for office
workers in Australia. 49% of Australian
office workers experience neck pain,
which is higher when compared with
office workers in Finland at 34%.
Also, office workers were three times
more likely to develop neck pain if they
were female and high psychological
stress appears to increase the chance of
experiencing neck pain.
Specially developed for neck and
shoulder pain, Tiger Balm Neck & Shoulder
Rub can help. It provides temporary
relief of tense, aching neck and shoulder
muscles. Formulated with natural active
ingredients wintergreen oil, eucalyptus
and mint oils, and with a soothing
fragrance, the non-greasy cream is
absorbed quickly and can be used
anytime, anywhere, even in the office.
Novartis Oncology has welcomed
the listing on the Pharmaceutical
Benefits Scheme (PBS) of Mekinist
(trametinib) for use in combination
with Tafinlar (dabrafenib) for the
treatment of patients with BRAFV600
mutation-positive Stage III and
Stage IV (metastatic) melanoma.
The listing follows the Government’s
announcement in the Federal Budget.
More than 10,000 Australians are treated
for melanoma each year and more than
1,200 Australians die from melanoma
Tafinlar + Mekinist has been
recommended by the Pharmaceutical
Benefits Advisory Committee (PBAC)
as a Managed entry Scheme (MeS).
The scheme agreed between the
Government and Novartis Oncology
requires the appraisal of future clinical
data to ensure the taxpayer is receiving
the best value for money. The listing of
this treatment for advanced melanoma
patients demonstrates Novartis
Oncology’s ongoing commitment to
partner with the Government and
the Department of Health to ensure
cancer patients have timely and
affordable access to medicines. Tafinlar
and Mekinist are both medicines
recently acquired by Novartis as part
of the recent global transaction with
Links Archive Australian Pharmacist August 2015 Australian Pharmacist October 2015 Navigation Previous Page Next Page